CA2774720C - Pharmaceutical composition comprising a macrolide immunosuppressant drug - Google Patents
Pharmaceutical composition comprising a macrolide immunosuppressant drug Download PDFInfo
- Publication number
- CA2774720C CA2774720C CA2774720A CA2774720A CA2774720C CA 2774720 C CA2774720 C CA 2774720C CA 2774720 A CA2774720 A CA 2774720A CA 2774720 A CA2774720 A CA 2774720A CA 2774720 C CA2774720 C CA 2774720C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- tacrolimus
- component
- composition according
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4055—Concentrating samples by solubility techniques
- G01N2001/4061—Solvent extraction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09012724.2 | 2009-10-08 | ||
| EP09012724A EP2308468A1 (en) | 2009-10-08 | 2009-10-08 | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| PCT/EP2010/064965 WO2011042485A1 (en) | 2009-10-08 | 2010-10-07 | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2774720A1 CA2774720A1 (en) | 2011-04-14 |
| CA2774720C true CA2774720C (en) | 2017-05-23 |
Family
ID=41435414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2774720A Active CA2774720C (en) | 2009-10-08 | 2010-10-07 | Pharmaceutical composition comprising a macrolide immunosuppressant drug |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8574562B2 (https=) |
| EP (2) | EP2308468A1 (https=) |
| JP (1) | JP5764792B2 (https=) |
| KR (1) | KR101790257B1 (https=) |
| CN (1) | CN102510752B (https=) |
| AU (1) | AU2010305404B2 (https=) |
| BR (1) | BR112012007332B1 (https=) |
| CA (1) | CA2774720C (https=) |
| ES (1) | ES2552803T3 (https=) |
| IN (1) | IN2012DN01559A (https=) |
| MX (1) | MX2012003800A (https=) |
| WO (1) | WO2011042485A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| AU2012274367A1 (en) * | 2011-06-23 | 2014-01-23 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| CN103830178B (zh) * | 2014-03-18 | 2017-01-11 | 深圳劲创生物技术有限公司 | 一种蒜氨酸微乳及其制备方法和应用 |
| EP3334416A1 (en) * | 2015-08-11 | 2018-06-20 | Eyesiu Medicines B.V. | Pegylated lipid nanoparticle with bioactive lipophilic compound |
| CA3020157C (en) * | 2016-04-04 | 2024-01-16 | Drug Delivery Solutions Limited | Topical composition comprising tacrolimus |
| US20200323793A1 (en) * | 2016-06-03 | 2020-10-15 | Avexxin As | Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor |
| CN106074386A (zh) * | 2016-08-31 | 2016-11-09 | 佛山市弘泰药物研发有限公司 | 一种依维莫司自微乳制剂及其制备方法 |
| CN109789111B (zh) | 2016-09-21 | 2021-11-16 | 埃维克辛公司 | 药物组合物 |
| EP3565520B1 (en) | 2017-01-06 | 2026-02-25 | Palvella Therapeutics, Inc. | Anhydrous compositions of mtor inhibitors and methods of use |
| US11766421B2 (en) | 2017-09-25 | 2023-09-26 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
| WO2019233722A1 (en) | 2018-06-08 | 2019-12-12 | Almirall, S.A. | Pharmaceutical composition comprising tacrolimus |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| KR20210141448A (ko) | 2018-12-27 | 2021-11-23 | 서피스 아프샐믹스 인코포레이티드 | 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법 |
| WO2021148619A1 (en) * | 2020-01-22 | 2021-07-29 | Bausch Health Ireland Limited | Topical compositions comprising a macrolide immunosuppressant |
| TWI769745B (zh) * | 2021-03-19 | 2022-07-01 | 國泰醫療財團法人國泰綜合醫院 | 醫藥組成物與製藥用途 |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12310981B2 (en) | 2021-05-10 | 2025-05-27 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| BE1030538B1 (nl) | 2022-05-18 | 2023-12-19 | Bogaert Gina Van | Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan |
| KR102727647B1 (ko) * | 2023-11-28 | 2024-11-08 | 장병모 | 칼시뉴린 억제제를 포함하는 피부질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK175235B1 (da) * | 1987-11-09 | 2004-07-19 | Novartis Ag | Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| GB2315216B (en) * | 1993-10-05 | 1998-10-14 | Ciba Geigy Ag | Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin |
| CN100335063C (zh) * | 1994-10-26 | 2007-09-05 | 诺瓦蒂斯有限公司 | 药物组合物 |
| GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| DE10036871A1 (de) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
| ATE468107T1 (de) * | 2001-11-01 | 2010-06-15 | Yissum Res Dev Co | Verfahren und zusammensetzung zur behandlung von trockenen augen |
| IL162496A0 (en) * | 2001-12-14 | 2005-11-20 | Jagotec Ag | Pharmaceutical compositions containing cyclosporin |
| BRPI0513395A (pt) * | 2004-07-16 | 2008-05-06 | Novartis Ag | uso de um esteróide para aumentar a permeabilidade cutánea |
| AU2005304035B2 (en) * | 2004-11-09 | 2010-07-22 | Santen Sas | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
| KR100678829B1 (ko) * | 2004-12-06 | 2007-02-05 | 한미약품 주식회사 | 타크로리무스의 경구용 마이크로에멀젼 조성물 |
| WO2006123354A2 (en) * | 2005-02-02 | 2006-11-23 | Mega Lifesciences Pvt. Ltd. | Oral pharmaceutical composition |
| DK1848431T3 (en) * | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
-
2009
- 2009-10-08 EP EP09012724A patent/EP2308468A1/en not_active Withdrawn
-
2010
- 2010-10-07 JP JP2012532587A patent/JP5764792B2/ja active Active
- 2010-10-07 EP EP10762917.2A patent/EP2485714B1/en active Active
- 2010-10-07 MX MX2012003800A patent/MX2012003800A/es active IP Right Grant
- 2010-10-07 ES ES10762917.2T patent/ES2552803T3/es active Active
- 2010-10-07 CA CA2774720A patent/CA2774720C/en active Active
- 2010-10-07 BR BR112012007332-0A patent/BR112012007332B1/pt active IP Right Grant
- 2010-10-07 CN CN201080042067.1A patent/CN102510752B/zh active Active
- 2010-10-07 WO PCT/EP2010/064965 patent/WO2011042485A1/en not_active Ceased
- 2010-10-07 AU AU2010305404A patent/AU2010305404B2/en active Active
- 2010-10-07 KR KR1020127009028A patent/KR101790257B1/ko active Active
- 2010-10-07 US US13/498,182 patent/US8574562B2/en active Active
-
2012
- 2012-02-21 IN IN1559DEN2012 patent/IN2012DN01559A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102510752B (zh) | 2015-08-05 |
| AU2010305404A1 (en) | 2012-03-08 |
| ES2552803T3 (es) | 2015-12-02 |
| IN2012DN01559A (https=) | 2015-06-05 |
| CA2774720A1 (en) | 2011-04-14 |
| MX2012003800A (es) | 2012-06-28 |
| EP2485714B1 (en) | 2015-09-09 |
| BR112012007332A2 (pt) | 2016-10-04 |
| US8574562B2 (en) | 2013-11-05 |
| AU2010305404B2 (en) | 2015-04-02 |
| BR112012007332B1 (pt) | 2021-07-13 |
| WO2011042485A1 (en) | 2011-04-14 |
| EP2308468A1 (en) | 2011-04-13 |
| JP2013507337A (ja) | 2013-03-04 |
| JP5764792B2 (ja) | 2015-08-19 |
| CN102510752A (zh) | 2012-06-20 |
| KR101790257B1 (ko) | 2017-10-26 |
| US20120184511A1 (en) | 2012-07-19 |
| EP2485714A1 (en) | 2012-08-15 |
| KR20120093865A (ko) | 2012-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2774720C (en) | Pharmaceutical composition comprising a macrolide immunosuppressant drug | |
| AU2022241500A1 (en) | Topical formulation | |
| JPH075473B2 (ja) | 局所適用シクロスポリン組成物 | |
| KR102386585B1 (ko) | 타크롤리무스를 포함하는 국소 조성물 | |
| JP4251988B2 (ja) | シクロスポリンを含む医薬製剤およびその使用 | |
| MXPA05010703A (es) | Composicion farmaceutica que comprende un inmunosupreror para usarse en el tratamiento de enfermedades de la piel. | |
| JP2021121617A (ja) | イソトレチノイン製剤ならびにその使用および方法 | |
| HK1167102A (en) | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug | |
| CA3240662A1 (en) | Stable formulations of shr0302 | |
| RU2538680C2 (ru) | Фармацевтическая композиция для лечения атопического дерматита и способ ее получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20151002 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - SMALL Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240923 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240923 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - SMALL Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250930 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250930 |